Drugs / SHR-8068
Trials 25
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07852325 | Jan → Dec 2024 | — | The Affiliated Hospital of Qingdao University | Completed | No outcome recorded |
| Phase 1/27 trials | ||||||
| Phase 1/2 | NCT07239596 | Jan 2026 → Dec 2030 expected | renal cell carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06859775 | Apr 2025 → Oct 2026 expected | — | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06589778 | Sep 2024 → Apr 2026 overdue | non-small cell lung carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06427239 | Jun 2024 → Jun 2027 expected | malignant pancreatic neoplasm | Fudan University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06373133 | May 2024 → Nov 2026 expected | colorectal cancer | West China Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05416775 | Aug 2022 → Jun 2026 | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05444088 | Aug 2022 → Jun 2026 | hepatocellular carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 211 trials | ||||||
| Phase 2 | NCT07704645 | Aug 2026 → Jun 2028 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07682272 | Jul 2026 → Jul 2027 expected | hepatocellular carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07503639 | Apr 2026 → Apr 2028 expected | colorectal cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07266025 | Jan 2026 → Jun 2030 expected | gastric adenocarcinoma, gastroesophageal adenocarcinoma | Shanghai Zhongshan Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07241767 | Nov 2025 → Nov 2027 expected | lung cancer | Jiangsu HengRui Medicine Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07110571 | Aug 2025 → Aug 2026 overdue | gastric cancer, gastroesophageal cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07071714 | Jul 2025 → Oct 2031 expected | colorectal cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07028281 | Jul 2025 → Dec 2028 expected | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06778031 | Feb 2025 → Jun 2028 expected | carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06465563 | Jul 2024 → Dec 2026 expected | biliary tract cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06247956 | Mar 2024 → Dec 2025 overdue | digestive system carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT07454720 | Mar 2026 → Nov 2032 expected | — | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06335355 | Mar 2024 → Oct 2028 expected | non-small cell lung carcinoma | Shanghai Shengdi Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT07691762 | Sep 2026 → Apr 2031 expected | hepatocellular carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07229625 | Jan 2026 → Dec 2029 expected | biliary tract cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT07170995 | Oct 2025 → Dec 2030 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06618664 | Oct 2024 → Oct 2026 expected | hepatocellular carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Comparator or background therapy5 trials | ||||||
| Phase 1/2 | NCT06754930 Background | Feb 2025 → Dec 2027 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06703177 Background | Feb 2025 → Jan 2026 overdue | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06639347 Background | Nov 2024 → May 2027 expected | urothelial carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06434103 Background | Oct 2024 | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Withdrawn | No outcome recorded Stop: Business |
| Phase 2 | NCT06844474 Background | Mar 2025 → Dec 2026 expected | non-small cell lung carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 30 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-8068 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07028281 ↗ |
| Action | Inhibit | “CTLA-4 inhibitors” NCT06373133 ↗ |
| Modality | Monoclonal antibody | “Anti-CTLA4 monoclonal antibody” NCT06373133 ↗ |
| Route | Intravenous | “SHR-8068: Sterile Injection, 50mg/10mL, Intravenous Infusion” NCT05416775 ↗ |
| Target | CTLA4 | “Anti-CTLA4 monoclonal antibody” NCT06373133 ↗ |